Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.
复制标题
DOI：
10.2807/1560-7917.es.2021.26.26.2100557
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Mandelboim M
中科院分区：
文献类型：
--
作者：
Lustig Y;Zuckerman N;Nemet I;Atari N;Kliker L;Regev-Yochay G;Sapir E;Mor O;Alroy-Preis S;Mendelson E;Mandelboim M
SARS-CoV-2 Delta（B.1.617.2）变异关注（VOC）和其他VOC正在欧洲蔓延。对36名医护人员（31名女性）接种Comirnaty（BNT 162 b2，BioNTech/Pfizer）疫苗后获得的血清进行微量中和试验，结果显示中和滴度与原始病毒相比显著降低倍数：γ（P.1）2.3，β（B.1.351）10.4，δ 2.1和2.6。α（B.1.1.7）变体的减少不显著。尽管较低，但Comirnaty赋予的对Delta和其他VOC的剩余中和能力可能具有保护作用。
SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.